2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-137951
    Metizolam 40054-68-0 99.30%
    Metizolam, a thienotriazolodiazepine, is the demethylated analogue of Etizolam. Metizolam exhibits psychomotor stabilizing, anxiolytic, sedative, myo-relaxant and amnestic effects.
    Metizolam
  • HY-137961
    Cannabigerol monomethyl ether 29106-17-0 98.04%
    Cannabigerol monomethyl ether is a monomethyl ether derivative of the canonical phytocannabinoids.
    Cannabigerol monomethyl ether
  • HY-137979
    Flunitrazolam 2243815-18-9 99.9%
    Flunitrazolam is an orally active designer Benzodiazepine. Flunitrazolam is biologically toxic, class in psychoactive substances.
    Flunitrazolam
  • HY-137994
    Deschloroetizolam 40054-73-7 ≥98.0%
    Deschloroetizolam is a designer Benzodiazepine. Deschloroetizolam is a psychoactive substance, with physical and cognitive effects.
    Deschloroetizolam
  • HY-138131
    SOD1-Derlin-1 inhibitor-1 840461-03-2 99.93%
    SOD1-Derlin-1 inhibitor-1 (compound 56-20) is an inhibitor of SOD1-Derlin-1 interaction. SOD1-Derlin-1 inhibitor-1 inhibits SOD1G93A-Derlin-1 complex with an IC50 value of 7.11 μM. SOD1-Derlin-1 inhibitor-1 can be used for the research of amyotrophic lateral sclerosis.
    SOD1-Derlin-1 inhibitor-1
  • HY-138649
    PB2 914940-24-2 99.88%
    PB2 is a tris(2-carboxyethyl)phosphine (TCEP) analogue increasing retinal ganglion (RGCs) cells survival after axotomy in vitro at nanomolar and picomolar concentrations. PB2 is substantially more permeable than TCEP. PB2, as a reducing agent, is highly neuroprotective for RGCs.
    PB2
  • HY-138695
    Orexin 2 Receptor Agonist 2 2114324-60-4 98.06%
    Orexin 2 Receptor Agonist 2 is a selective orexin 2 receptor agonist, extracted from patent WO2017135306A1, example 16.
    Orexin 2 Receptor Agonist 2
  • HY-139331
    20S Proteasome-IN-1 858557-69-4 99.13%
    20S Proteasome-IN-1 is a 26S proteasome inhibitor extracted from patent WO2006128196A2 compound 2. 20S Proteasome-IN-1 has the potential for cancer, immune-related disorders, inflammation, ischemic conditions, neurodegenerative disorders and other diseases research.
    20S Proteasome-IN-1
  • HY-139630
    ANAT inhibitor-2 1048244-34-3 99.23%
    ANAT inhibitor-2 is a ANAT inhibitor for canavan disease, with an IC50 value of 20 μM.
    ANAT inhibitor-2
  • HY-141508
    Flazin 100041-05-2 99.64%
    Flazin is a non-enzymatic protein glycation inhibitor, also inhibits peroxynitrite (ONOO-), with an IC50 value of 85.31 μM for bovine serum albumin (BSA) glycation and an EC50 value of 71.99 μM for ONOO-. Flazin can be used for researching diabetes and neuronal disorders. Flazin also can used as a lipid droplet (LD) regulator against lipid disorders, and a xanthine oxidase (XOD) inhibitor.
    Flazin
  • HY-14151S
    Prucalopride-13C,d3 2140306-00-7 99.0%
    Prucalopride-13C,d3 is the 13C- and deuterium labeled Prucalopride.
    Prucalopride-13C,d3
  • HY-141632
    Sphinganine-C17 32164-02-6 99.09%
    Sphinganine-C17 (Heptadecasphinganine) is a synthetic bioactive sphingolipid and an isomer of sphinganine. Sphinganine-C17 inhibits the growth of Candida glabrata and Candida albicans with a minimum bactericidal concentration (MBC) of 0.5 μg/mL for both. Sphinganine-C17 can be used as an internal standard for the chromatographic analysis of sphingosine compounds.
    Sphinganine-C17
  • HY-14261S
    Vilazodone-d8 1794789-93-7 99.0%
    Vilazodone-d8 is the a deuterium labeled vilazodone, which is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist.
    Vilazodone-d8
  • HY-14280R
    Entacapone (Standard) 130929-57-6 99.24%
    Entacapone (Standard) is the analytical standard of Entacapone. This product is intended for research and analytical applications. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders.
    Entacapone (Standard)
  • HY-14280S
    Entacapone-d10 1185241-19-3 98.0%
    Entacapone-d10 is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 μM). Entacapone can be used for the research of Parkinson's disease. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders.
    Entacapone-d10
  • HY-142868
    ONO-8713 459411-08-6 99.0%
    ONO-8713 is a selective prostaglandin E receptor subtype EP1 antagonist.
    ONO-8713
  • HY-14316C
    Tebanicline tosylate 198283-74-8 98.65%
    Tebanicline tosylate, an analogue of epibatidine, is a neuronal nicotinic acetylcholine receptor agonist. Tebanicline tosylate exhibits potent antinociceptive effects and has a high affinity for the α4β2 neuronal nicotinic acetylcholine receptor subunit in the central nervous system.
    Tebanicline tosylate
  • HY-143792
    HTT-D3 2254502-89-9 98%
    HTT-D3 is a potent and orally active huntingtin (HTT) splicing modulator. HTT-D3 acts by promoting the inclusion of a pseudoexon containing a premature termination codon (stop-codon psiExon), leading to HTT mRNA degradation and reduction of HTT levels. HTT-D3 reduces p-glycoprotein (P-gp) efflux, and can be uesd for Huntington's disease research.
    HTT-D3
  • HY-145153
    S-777469 885496-53-7 98.19%
    S-777469 is a selective and orally available cannabinoid type 2 receptor (CB2) agonist with a Ki of 36 nM. S-777469 significantly suppresses compound 48/80-induced scratching behavior in mice in a dose-dependent manner. S-777469 produces its antipruritic effects by inhibiting itch signal transmission through CB2 agonism.
    S-777469
  • HY-14538A
    Haloperidol hydrochloride 1511-16-6 98%
    Haloperidol hydrochloride is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.
    Haloperidol hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity